DA-7503

DA-7503 is a novel, potent, and selective small molecule inhibitor of tau aggregation developed for the treatment of Alzheimer's disease (AD) and other tauopathies. It selectively binds to pathological and detached forms of tau monomers, inhibiting their oligomerization and preventing the transition from soluble protein to insoluble aggregates. This action reduces intracellular tau oligomers, protofibrils, filaments, and neurofibrillary tangles in vitro and in vivo. DA-7503 has demonstrated neuroprotective effects by alleviating memory impairment and reducing brain pathology in AD animal models. The drug acts primarily on intracellular pathological tau, offering advantages over antibody-based or non-selective inhibitors due to its oral availability, brain penetration, specificity for pathological tau species, and potential as a first-in-class disease-modifying therapy[1][2][3][5][6]. Developed by Dong-A ST.